108 related articles for article (PubMed ID: 12089783)
21. [C-erbB-2, EGF receptor, p53 and PCNA. The prognostic significance of recent tumor markers for lymph node negative breast cancer].
Schönborn I; Minguillon C; Lichtenegger W; Zschiesche W; Spitzer E
Geburtshilfe Frauenheilkd; 1995 Oct; 55(10):566-71. PubMed ID: 8543129
[TBL] [Abstract][Full Text] [Related]
22. Clinical implications of CSN6 protein expression and correlation with mutant-type P53 protein in breast cancer.
Wang W; Tang M; Zhang L; Xu X; Qi X; Yang Y; Jin F; Chen B
Jpn J Clin Oncol; 2013 Dec; 43(12):1170-6. PubMed ID: 24106298
[TBL] [Abstract][Full Text] [Related]
23. Immunoreactivity of p53, Ki-67, and c-erbB-2 in phyllodes tumors of the breast in correlation with clinical and morphologic features.
Shpitz B; Bomstein Y; Sternberg A; Klein E; Tiomkin V; Kaufman A; Groisman G; Bernheim J
J Surg Oncol; 2002 Feb; 79(2):86-92. PubMed ID: 11815995
[TBL] [Abstract][Full Text] [Related]
24. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
Göhring UJ; Scharl A; Ahr A
Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
[TBL] [Abstract][Full Text] [Related]
25. Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas.
Bongiorno PF; Whyte RI; Lesser EJ; Moore JH; Orringer MB; Beer DG
J Thorac Cardiovasc Surg; 1994 Feb; 107(2):590-5. PubMed ID: 7905543
[TBL] [Abstract][Full Text] [Related]
26. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.
Thor AD; Moore DH II; Edgerton SM; Kawasaki ES; Reihsaus E; Lynch HT; Marcus JN; Schwartz L; Chen LC; Mayall BH
J Natl Cancer Inst; 1992 Jun; 84(11):845-55. PubMed ID: 1317462
[TBL] [Abstract][Full Text] [Related]
27. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erb B-2 in lymph node-negative breast cancer.
O'Malley FP; Saad Z; Kerkvliet N; Doig G; Stitt L; Ainsworth P; Hundal H; Chambers AF; Turnbull DI; Bramwell V
Hum Pathol; 1996 Sep; 27(9):955-63. PubMed ID: 8816892
[TBL] [Abstract][Full Text] [Related]
28. EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer.
Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y
Eur J Surg Oncol; 2002 Jun; 28(4):383-7. PubMed ID: 12099646
[TBL] [Abstract][Full Text] [Related]
29. Correlations of telomere length, P53 mutation, and chromosomal translocation in soft tissue sarcomas.
Liu C; Li B; Li L; Zhang H; Chen Y; Cui X; Hu J; Jiang J; Qi Y; Li F
Int J Clin Exp Pathol; 2015; 8(5):5666-73. PubMed ID: 26191279
[TBL] [Abstract][Full Text] [Related]
30. Prognostic role of apoptotic, Bcl-2, c-erbB-2 and p53 tumor markers in salivary gland malignancies.
Nagler RM; Kerner H; Ben-Eliezer S; Minkov I; Ben-Itzhak O
Oncology; 2003; 64(4):389-98. PubMed ID: 12759537
[TBL] [Abstract][Full Text] [Related]
31. Clinical and pathological factors influencing the survival of breast cancer patients with malignant pleural effusion.
Santos GT; Prolla JC; Camillo ND; Zavalhia LS; Ranzi AD; Bica CG
J Bras Pneumol; 2012; 38(4):487-93. PubMed ID: 22964933
[TBL] [Abstract][Full Text] [Related]
32. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
[TBL] [Abstract][Full Text] [Related]
33. Molecular testing of solid tumors.
Igbokwe A; Lopez-Terrada DH
Arch Pathol Lab Med; 2011 Jan; 135(1):67-82. PubMed ID: 21204713
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the immunohistochemical expression of EGFR, c-erbB2 and p53 protein between primary and recurrent breast cancer.
Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y
Breast Cancer; 2002; 9(2):111-7. PubMed ID: 12016390
[TBL] [Abstract][Full Text] [Related]
35. Correlations between HER2 Expression and Other Prognostic Factors in Breast Cancer: Inverse Relations with the Ki-67 Index and P53 Status.
Payandeh M; Shahriari-Ahmadi A; Sadeghi M; Sadeghi E
Asian Pac J Cancer Prev; 2016; 17(3):1015-8. PubMed ID: 27039719
[TBL] [Abstract][Full Text] [Related]
36. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification.
Arnould L; Arveux P; Couturier J; Gelly-Marty M; Loustalot C; Ettore F; Sagan C; Antoine M; Penault-Llorca F; Vasseur B; Fumoleau P; Coudert BP
Clin Cancer Res; 2007 Nov; 13(21):6404-9. PubMed ID: 17975153
[TBL] [Abstract][Full Text] [Related]
37. Common patterns of genetic evolution in human solid tumors.
Shackney SE; Shankey TV
Cytometry; 1997 Sep; 29(1):1-27. PubMed ID: 9298807
[TBL] [Abstract][Full Text] [Related]
38. Triple-negative breast cancer: current state of the art.
Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S
Tumori; 2010; 96(6):875-88. PubMed ID: 21388048
[TBL] [Abstract][Full Text] [Related]
39. Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas.
Smith CA; Pollice AA; Gu LP; Brown KA; Singh SG; Janocko LE; Johnson R; Julian T; Hyams D; Wolmark N; Sweeney L; Silverman JF; Shackney SE
Clin Cancer Res; 2000 Jan; 6(1):112-26. PubMed ID: 10656439
[TBL] [Abstract][Full Text] [Related]
40. A preliminary study of CA15-3, c-erbB-2, epidermal growth factor receptor, cathepsin-D, and p53 in saliva among women with breast carcinoma.
Streckfus C; Bigler L; Tucci M; Thigpen JT
Cancer Invest; 2000; 18(2):101-9. PubMed ID: 10705871
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]